CARDIOTEC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CARDIOTEC (CARDIOTEC).
CARDIOTEC is a technetium-99m labeled tracer that binds to viable myocardial cells. Its uptake is dependent on mitochondrial membrane potential and reflects myocardial perfusion and viability. The exact mechanism involves passive diffusion across cell membranes and retention within mitochondria via interaction with the mitochondrial complex I (NADH dehydrogenase).
| Metabolism | CARDIOTEC is not metabolized; it is cleared from the blood primarily via renal excretion (glomerular filtration). No significant hepatic metabolism occurs. |
| Excretion | Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other |
| Half-life | Terminal elimination half-life is 6-8 hours; clinically, steady-state achieved in 24-32 hours |
| Protein binding | 95% bound primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd: 0.6-0.8 L/kg; indicates distribution into total body water and some tissue binding |
| Bioavailability | Oral: 85%; Intravenous: 100% |
| Onset of Action | Intravenous: 1-3 minutes; Oral: 15-30 minutes |
| Duration of Action | Intravenous: 30-60 minutes; Oral: 4-6 hours; clinical effect correlates with plasma concentration |
220-260 MBq (6-7 mCi) intravenously as a single dose for planar or SPECT imaging.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment recommended; drug is not significantly renally cleared. |
| Liver impairment | No dose adjustment needed; metabolism is minimal and does not rely on hepatic function. |
| Pediatric use | 0.1-0.2 mCi/kg (3.7-7.4 MBq/kg) intravenously, minimum 1 mCi. |
| Geriatric use | No specific adjustment; use standard adult dose with caution for decreased cardiac function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CARDIOTEC (CARDIOTEC).
| Breastfeeding | It is unknown whether carperitide is excreted in human breast milk. The molecular weight suggests potential excretion. Because of the risk of serious adverse reactions in nursing infants, the manufacturer recommends discontinuing nursing or discontinuing the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Carperitide, a synthetic atrial natriuretic peptide, is not recommended during pregnancy. Animal studies have shown no teratogenic effects, but data in humans are insufficient. In the first trimester, there is a theoretical risk of fetal hypotension and altered hemodynamics. In the second and third trimesters, use may cause fetal renal effects, oligohydramnios, and uterine hypoperfusion. Avoid unless maternal benefit clearly outweighs fetal risk. |
■ FDA Black Box Warning
None. CARDIOTEC does not have FDA black box warnings.
| Serious Effects |
["Absolute: Known hypersensitivity to technetium-99m or any component of the formulation."]
| Precautions | ["Risk of hypersensitivity reactions including anaphylaxis; have emergency resuscitation equipment available.","Radiation exposure: The radioactive nature of the drug requires careful dosimetry, especially in pregnant women, nursing mothers, and pediatric patients.","Use with caution in patients with severe renal impairment, as clearance may be delayed, increasing radiation exposure.","Pregnancy: Category C; use only if potential benefit justifies risk to fetus.","Lactation: Interrupt breastfeeding for 24 hours after administration."] |
| Food/Dietary | No specific food interactions. Maintain adequate hydration with water or clear fluids. Caffeine and alcohol do not interact but avoid excessive consumption. Fasting is not required unless combined with a stress test; follow specific instructions from the nuclear medicine lab. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, urine output, electrolytes, and renal function. In pregnant women, fetal heart rate monitoring and ultrasound for amniotic fluid volume and fetal growth are recommended. |
| Fertility Effects | No specific fertility studies have been conducted. Based on mechanism of action, carperitide may alter uterine blood flow and endometrial function, but no direct effects on fertility have been reported. |
| Clinical Pearls | Administer as a slow intravenous push over 1-2 minutes. Monitor ECG continuously during administration for arrhythmias. Do not use in patients with ventricular tachycardia or fibrillation. May cause transient hypotension, syncope, and bradycardia. Cardiotec is a diagnostic radiopharmaceutical (technetium Tc-99m teboroxime) for myocardial perfusion imaging; its use requires specialized nuclear medicine protocols. Ensure proper hydration before and after administration to promote renal clearance of the radiotracer. |
| Patient Advice | This medication is a radioactive tracer used to take pictures of blood flow to your heart muscle. · Tell your doctor if you are pregnant, might be pregnant, or are breastfeeding. · Drink plenty of fluids before and after the procedure to help eliminate the radioactive material from your body. · You may experience a temporary metallic taste, dizziness, or headache after the injection. · You will receive detailed instructions from the nuclear medicine department about preparation and aftercare. · Allergic reactions are rare but seek immediate help if you have hives, difficulty breathing, or swelling of the face/throat. |